MDT perspectives on biologic treatment selection in severe type 2 asthm episode artwork

EPISODE · Jan 26, 2022 · 16 MIN

MDT perspectives on biologic treatment selection in severe type 2 asthm

from touchPODCAST · host touchpodcast

touchMDT for touchRESPIRATORY Listen to key experts from a multidisciplinary team explore the use of endotyping and biomarkers in guiding biologic treatment selection for patients with severe type 2 asthma. The multidisciplinary team  Allergist: Professor Ioana Agache, Romania Primary care physician: Professor Barbara Yawn, USA Pulmonologist: Professor Alberto Papi, Italy This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchrespiratoryime.org/strategies-for-the-management-of-severe-type-2-asthma-expert-insight-into-optimizing-care/

Episode metadata supplied by the publisher feed · Published Jan 26, 2022

Embed this episode

Ready to play

MDT perspectives on biologic treatment selection in severe type 2 asthm

0:00 16:22

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 16 minutes long.

When was this touchPODCAST episode published?

This episode was published on January 26, 2022.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!